pneumonia%20-%20community-acquired
PNEUMONIA - COMMUNITY-ACQUIRED
Community-Acquired Pneumonia (CAP) is an acute infection of the pulmonary parenchyma accompanied by symptoms of acute illness and abnormal chest findings.
It is a lower respiratory tract infection acquired in the community within 24 hours to <2 weeks or occurring ≤48 hours of hospital admission in patients who do not meet the criteria for healthcare-associated pneumonia.
It occurs at the highest rates in the very young and the very old.
Potentially life-threatening especially in older adults and those with comorbid disease.

Pneumonia - Community-Acquired Drug Information

Drug Information

Indication: Short-term treatment of upper & lower resp tract, skin & soft tissue, GUT infections. Tab & inj Sh...

Indication: Acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired & nosoco...

Indication: Prevention of influenza disease caused by influenza types A & B viruses.

Indication: Infections of nose-pharynx tract (tonsillitis, pharyngitis) & of paranasal sinuses; lower resp tract: bron...

Indication: Infections of the resp tract, middle ear (otitis media), paranasal sinuses (sinusitis) especially caused by gm...

Indication: Active immunisation for the prevention of pneumococcal disease caused by Strep pneumoniae serotypes 1, 3, 4, 5...

Indication: Upper & lower resp tract infection, upper & lower UTI, peritonitis, cholecystitis, cholangitis & o...

Indication: Lower resp tract, complicated & uncomplicated UTI, intra-abdominal, skin & skin structure infections; ...

Indication: Complicated skin & skin structure infections, complicated intra-abdominal infections (cIAI) in adults.

Indication: Upper & lower resp tract infections including sinusitis, otitis media & epiglottitis, bacterial pneumo...

1  /  25
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 16 Sep 2020
Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 07 Oct 2020

In patients with severe eosinophilic asthma, cessation of mepolizumab may lead to increased exacerbations and reductions in asthma control, according to results of the COMET* trial.